Changes of Acute Kidney Injury Epidemiology during the COVID-19 Pandemic: A Retrospective Cohort Study.
Pasquale EspositoElisa RussoDaniela PicciottoFrancesca CappadonaBattaglia YuriGiovanni Battista TraversoFrancesca ViazziPublished in: Journal of clinical medicine (2022)
To evaluate the impact of the Coronavirus Disease-19 (COVID-19) pandemic on the epidemiology of acute kidney injury (AKI) in hospitalized patients, we performed a retrospective cohort study comparing data of patients hospitalized from January 2016 to December 2019 (pre-COVID-19 period) and from January to December 2020 (COVID-19 period, including both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative and positive patients). AKI was classified by evaluating the kinetics of creatinine levels. A total of 51,681 patients during the pre-COVID-19 period and 10,062 during the COVID-19 period (9026 SARS-CoV-2-negative and 1036 SARS-CoV-2-positive) were analyzed. Patients admitted in the COVID-19 period were significantly older, with a higher prevalence of males. In-hospital AKI incidence was 31.7% during the COVID-19 period (30.5% in SARS-CoV-2-negative patients and 42.2% in SARS-CoV-2-positive ones) as compared to 25.9% during the pre-COVID-19 period ( p < 0.0001). In the multivariate analysis, AKI development was independently associated with both SARS-CoV-2 infection and admission period. Moreover, evaluating the pre-admission estimated glomerular filtration rate (eGFR) we found that during the COVID-19 period, there was an increase in AKI stage 2-3 incidence both in patients with pre-admission eGFR < 60 mL/min/1.73 m 2 and in those with eGFR ≥ 60 mL/min/1.73 m 2 ("de novo" AKI). Similarly, clinical outcomes evaluated as intensive care unit admission, length of hospital stay, and mortality were significantly worse in patients admitted in the COVID-19 period. Additionally, in this case, the mortality was independently correlated with the admission during the COVID-19 period and SARS-CoV-2 infection. In conclusion, we found that during the COVID-19 pandemic, in-hospital AKI epidemiology has changed, not only for patients affected by COVID-19. These modifications underline the necessity to rethink AKI management during health emergencies.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- acute kidney injury
- end stage renal disease
- intensive care unit
- chronic kidney disease
- ejection fraction
- newly diagnosed
- emergency department
- small cell lung cancer
- healthcare
- prognostic factors
- peritoneal dialysis
- mental health
- public health
- cardiac surgery
- coronary artery disease
- tyrosine kinase
- extracorporeal membrane oxygenation
- cardiovascular events
- epidermal growth factor receptor
- climate change
- acute respiratory distress syndrome
- mechanical ventilation